Blood Transfusion and Component Therapy

Blood transfusion and component therapy is the administration of red cells, plasma, platelets, and related products to patients who are bleeding, anaemic, or deficient in coagulation factors. In critical and emergency care, nurses verify compatibility, administer components, and monitor for transfusion reactions, while clinical teams weigh the evidence on when to transfuse.

Definition

Blood transfusion is the intravenous administration of whole blood or, more usually, separated blood components — red cells, plasma, platelets, and cryoprecipitate — to replace deficient or lost blood elements; component therapy refers to selecting and giving the specific component a patient needs.

Scope

This entry covers the major blood components and their broad indications, the concept of restrictive versus liberal transfusion thresholds, the place of transfusion in major haemorrhage, and the safe administration and monitoring responsibilities surrounding it. It presents these as reference essentials and does not specify transfusion triggers or volumes for an individual patient.

Core questions

• What are the main blood components, and what broad clinical needs do they address?
• What does the evidence show about restrictive versus liberal red-cell transfusion thresholds?
• How does transfusion fit into the management of major haemorrhage, and what monitoring does safe administration require?

Key concepts

• Blood components (red cells, plasma, platelets, cryoprecipitate)
• Restrictive versus liberal transfusion thresholds
• ABO and Rh compatibility
• Pretransfusion verification and patient identification
• Transfusion reactions
• Massive transfusion and major haemorrhage
• Component therapy in coagulopathy

Mechanisms

Donated blood is separated into components so that patients receive the specific element they lack: red cells to restore oxygen-carrying capacity, plasma and cryoprecipitate to replace coagulation factors, and platelets to support haemostasis. Compatibility testing (ABO and Rh) and patient identification guard against haemolytic reactions, and a range of immune and non-immune reactions can follow transfusion. In major haemorrhage, blood loss depletes both volume and clotting capacity, so balanced replacement of red cells, plasma, and platelets is used to support the circulation and coagulation (Cannon, 2018).

Clinical relevance

Safe transfusion practice — correct identification, compatibility checking, administration, and vigilance for reactions — is a defined responsibility in critical and emergency nursing, and the evidence on transfusion thresholds informs how teams use a limited resource. This entry is educational reference material describing components, evidence, and safety principles; it is not a protocol for deciding when or how much to transfuse a particular patient.

Evidence & guidelines

The landmark TRICC trial found that a restrictive red-cell transfusion strategy was at least as safe as a liberal strategy in many critically ill patients (Hebert et al., 1999), and AABB clinical practice guidelines synthesize subsequent evidence on transfusion thresholds and red-cell storage (Carson et al., 2016). Reviews of haemorrhagic shock describe the role of balanced component resuscitation in major bleeding (Cannon, 2018).

Debates

Restrictive versus liberal transfusion thresholds

Whether to transfuse at a higher or lower haemoglobin threshold has been examined in randomized trials and guidelines, with evidence broadly favouring restrictive strategies in many stable patients while recognizing exceptions.

Seminal works

• hebert-1999
• carson-2016
• cannon-2018

Frequently asked questions

What does a restrictive transfusion strategy mean?

A restrictive strategy transfuses red cells only when haemoglobin falls below a lower threshold, rather than maintaining a higher level. Randomized evidence and guidelines indicate this approach is at least as safe as a liberal strategy for many stable patients.

Why is patient identification so important before a transfusion?

Giving incompatible blood can cause a serious haemolytic reaction, so verifying patient identity and blood-component compatibility before administration is a central safety step in transfusion practice.